Dallas, Texas 11/20/2013 (Financialstrend) – The Boston Scientific Corporation (NYSE:BSX) Vercise Deep Brain Stimulation System has received the CE Mark-approval. It is used in the treatment of intractable-primary & secondary dystonia, a neurological-movement disorder that is characterized by the involuntary muscle contractions.
Dystonia affects over 500,000 people in Europe, and included children and adults. This is the 3rd most-common movement-disorder after Parkinson’s disease & essential tremor. Its Symptoms are involuntary muscle contractions that are accompanied by twisting and repetitive movements / abnormal postures. All of these can be very painful & debilitating.
The Boston Scientific Corporation (NYSE:BSX) Vercise DBS System is the very 1st system that has been designed to selectively-stimulate different targeted areas of the human brain to customize therapy & manage Parkinson’s disease symptoms. This system offers new hope for those patients with dystonia.
In Tuesday’s trading session, Boston Scientific Corporation (NYSE:BSX) rose by 3.37%. The shares opened at a price of $11.63, which touched the intraday high of $12.05 and headed to a close of $11.96. Approximately 13.01M shares were traded on Tuesday and an average volume of 13.70 million shares were traded over a 30 day period. The 52-week low of Boston Scientific Corporation (NYSE:BSX) shares is $5.17 and its 52-week high is $12.48. The company has a market capitalization of $15.97 billion.
About the company
Boston Scientific Corporation (NYSE:BSX) is a company that develops, manufactures & markets medical devices that are utilized in a variety of different interventional medical specialties. In the year that ended in 31st December 2011, Boston Scientific Corporation (NYSE:BSX)’s products had been offered for sale by 7 core businesses: 1- Interventional Cardiology, 2- CRM, 3- Endoscopy, 4- Peripheral Interventions, 5- Urology/Women’s Health, 6- Neuromodulation, and 7- Electrophysiology. In 2011 January, Boston Scientific Corporation (NYSE:BSX) completed acquiring Intelect Medical, Inc. In 2012 June, Boston Scientific Corporation (NYSE:BSX) acquired Cameron Health, Inc. located in San Clemente, California